Southland Equity Partners LLC Decreases Position in Eli Lilly and Company (NYSE:LLY)

Southland Equity Partners LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 3.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 519 shares of the company’s stock after selling 17 shares during the period. Southland Equity Partners LLC’s holdings in Eli Lilly and Company were worth $428,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. FPC Investment Advisory Inc. lifted its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after buying an additional 43 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $43,000. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter valued at $48,000. Capital A Wealth Management LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at $63,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $818.56 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market cap of $775.78 billion, a P/E ratio of 69.90, a P/E/G ratio of 1.40 and a beta of 0.41. The business’s fifty day moving average is $775.43 and its two-hundred day moving average is $801.50. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the firm posted $2.58 EPS. Eli Lilly and Company’s revenue for the quarter was up 45.2% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.